Author: Marković, Ana Koljevic ; Bobić-Radovanović, Anica ; Krivokapic, Zoran ; Galun, Danijel ; Stojković, Milica ; Milovanović, Jovica ; Sobić-Šaranović, Dragana ; Saranović, Djordjije ; Artiko, Vera ; Petrović, Milorad ; Obradović, Vladimir ; Milovanović, Aleksandar ; Radovanović, Nebojša ; Stojković, Mirjana ; Antić, Andrija ; Zuvela, Marinko

AIMTo assess the clinical role of monoclonal immunoscintigraphy for the detection of metastasis and recurrence of colorectal cancer.METHODSMonoclonal immunoscintigraphy was performed in patients operated on for colorectal adenocarcinoma suspected of local recurrence and metastatic disease. The results were compared with conventional diagnostics.RESULTSImmunoscintigraphic investigation was done in 53 patients. Tumor recurrence occurred in 38 patients, and was confirmed by other diagnostic modalities in 35. In 15 patients, immunoscintigraphic findings were negative, and confirmed in 14 with other diagnostic methods. Comparative analysis confirmed good correlation of immunoscintigraphic findings and the results of conventional diagnostics and the level of tumor marker carcinoembryonic antigen. Statistical analysis of parameters of radiopharmaceutical groups imacis, indimacis and oncoscint presented homogenous characteristics all of three radiopharmaceuticals. The analysis of immunoscintigraphic target focus was clearly improved using tomography.CONCLUSIONImmunoscintigraphy is highly specific and has a good predictive value in local recurrence of colorectal cancer.

25 Nov 2001·Colorectal DiseaseQ3 · MEDICINE

Immunoscintigraphy and intra‐operative radioimmunodetection in the treatment of colorectal carcinoma

Q3 · MEDICINE

Article

Author: D. Simkovic ; J. Bedrna ; Z. Voboril ; J. Vizda ; P. Hladik ; L. Strnad ; K. Smejkal

PurposeIntra‐operative radioimmunodetection of malignant involved lymph nodes follows the pre‐operative immunoscintigraphy in the treatment of patients with colorectal carcinoma. The aims of this clinical study were to determine the sensitivity of the method, to compare the results in study when using Oncoscint and CEA‐Scan and to evaluate the importance of the method of surgery and postoperative adjuvant therapy.Patients and methods121 patients with colorectal tumours (106 primary and 15 recurrent) were operated on using radioimmunoguided surgery (RIGS). The study compared results of pre‐operative immunoscintigraphy, intra‐operative radioimmunodetection and postoperative histological examination. Histological investigation used classical H&E staining. In histologically negative and RIGS positive cases the immunohistochemical investigation was supplemented. Two radiopharmaceuticals were used Oncoscint CR 103 (MAb B72.3, Satumomab Pendetide), labelled with 111In in 56 patients and CEA‐Scan (IMMU 4‐Fab′ fragments MAb against CEA, Arcitumomab), labelled with 99mTc in 65 patients.ResultsThe relationship between RIGS positive results and histological examination was statistically assessed after 38 operations and the most acceptable RIGS evaluating index was determined. All subsequent results were evaluated by this index. Immunoscintigraphy of tumour was positive in 112 cases (92.6%). Fifty‐five RIGS positive cases of malignant infiltrated lymph nodes were confirmed by 43 histologically positive examinations (78%). In this group 9 cases were discovered only by immunohistochemistry. Sixty‐six remaining RIGS negative results were confirmed in 62 (94%) cases by negative histology.ConclusionsBoth immunoscintigraphy and RIGS enable one to make a more accurate diagnosis. While treating the primary disease the use of RIGS may help in assessment of necessary extent of operation performance and in staging of the disease by revealing occult lymph nodes involved. Pre‐operative immunoscintigraphy seems to be a useful diagnostic method for detection of tumour recurrence. When comparing two radiopharmaceuticals used, CEA‐Scan seems to be more suitable for diagnostic studies, but using the Oncoscint for tumour recurrence detection had some specific benefit, too.

01 Sep 1998·Journal of nuclear medicine technology

Indium-111 satumomab pendetide: the first FDA-approved monoclonal antibody for tumor imaging.

Article

Author: Bohdiewicz, P J

OBJECTIVEColon cancer is the second most common cause of cancer mortality. Ovarian cancer is the most common gynecologic malignancy cause of death in women. A labeled monoclonal antibody attaches to a tumor-associated antigen and allows these tumor masses to be imaged or treated, depending on the radionuclide used. Indium-111 satumomab pendetide was the first labeled monoclonal antibody to be approved by the Food and Drug Administration (FDA) for tumor imaging. It is reactive with most colorectal and ovarian cancers, as well as other cancers. After reading this article, the technologist will understand the FDA approval process, phase trial results, safety and adverse reactions, human antimurine antibody response, indications, imaging protocol, and strengths and weaknesses of imaging with satumomab pendetide. Representative cases are presented.

100 Deals associated with 111 In-satumomab pendetide

External Link

KEGG	Wiki	ATC	Drug Bank
D04528	111 In-satumomab pendetide	V09IB02	DB00057

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Colorectal Cancer	US	CytoGen, Inc.	29 Dec 1992
Ovarian Cancer	US	CytoGen, Inc.	29 Dec 1992

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis